Details of Disease

General Information of Disease (ID: DIS7JDYJ)

Disease Name Gastrointestinal disease
Synonyms
stomach or intestinal disorder; git disease; gastrointestinal system disorder; gastrointestinal system disease; gastrointestinal disorder; gastrointestinal disease; gastroenteropathy; gastroenterological system disorder; gastroenterological system disease; disorder of digestive system; disease or disorder of digestive system; disease of digestive system; digestive system disorder; digestive system disease or disorder; digestive system disease; digestive disease; alimentary system disease
Disease Class DE2Z: Digestive system disease
Definition A disease or disorder that involves the digestive system.
Disease Hierarchy
DISH7H5I: Human disease
DIS7JDYJ: Gastrointestinal disease
ICD Code
ICD-11
ICD-11: DE2Z
Expand ICD-11
'DE2Z
Expand ICD-10
'XI; 'K63.4; 'K63.8; 'K63.9; 'K93.8
Disease Identifiers
MONDO ID
MONDO_0004335
UMLS CUI
C4023588
MedGen ID
892790
HPO ID
HP:0011024

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 12 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Alvimopan DMHR8KW Approved Small molecular drug [1]
AMI-121 DM7KT0M Approved NA [2]
Barium sulfate DMPEL5U Approved Small molecular drug [2]
Cisapride DMY7PED Approved Small molecular drug [3]
Domperidone DMBDPY0 Approved Small molecular drug [4]
FerriSeltz DMVX0DH Approved Small molecular drug [2]
Hyoscyamine DM804UR Approved Small molecular drug [5]
Indocyanine green DM2NQUY Approved Small molecular drug [6]
Mepenzolate DM8YU2F Approved Small molecular drug [7]
MM-Q01 DMAGVIU Approved NA [2]
SonoRx DMNKTDC Approved NA [2]
Xylose DMAR467 Approved Small molecular drug [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 Drug(s)
This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
TZP-101 DMOE582 Phase 2b Small molecular drug [8]
AZD-0865 DMM0N1F Phase 2 Small molecular drug [9]
CP-601927 DMKJFDM Phase 2 Small molecular drug [10]
FP-0110 DM5LMWA Phase 2 NA [11]
TD-8954 DM3C9NV Phase 2 Small molecular drug [12]
KOS-2187 DM4953W Phase 1 Small molecular drug [13]
NU-206 DMSWJ6D Phase 1 NA [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Drug(s)
This Disease is Treated as An Indication in 4 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
PMID27998201-Compound-5 DMVZ0ND Patented Small molecular drug [15]
Quinazoline derivative 11 DMAH435 Patented Small molecular drug [16]
Quinazoline derivative 12 DMVKZU2 Patented Small molecular drug [16]
Quinazoline derivative 13 DMFU6OD Patented Small molecular drug [16]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 13 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Oralex DMZ89OV Discontinued in Phase 2 NA [17]
Tarazepide DMX6ZYE Discontinued in Phase 2 Small molecular drug [18]
SLV-311 DM5TJIY Discontinued in Phase 1 NA [19]
TD-2749 DMCA97F Discontinued in Phase 1 NA [20]
A-70276 DM9KNFZ Terminated NA [21]
AZD-5745 DMKLCC0 Terminated NA [22]
AZD-9139 DMRXUIZ Terminated NA [23]
BCH-150 DMNH9A6 Terminated NA [24]
Heparin-EGF-like factor DMMXG2I Terminated NA [25]
PV-802 DMN3168 Terminated NA [26]
SK-951 DM6RVXU Terminated Small molecular drug [27]
SR-58894A DMQUF9I Terminated NA [28]
YM-022 DM97ULM Terminated Small molecular drug [29]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Drug(s)
This Disease is Treated as An Indication in 10 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
2-NAP DM2FTIC Investigative Small molecular drug [30]
Asperlicin DMAY2N3 Investigative Small molecular drug [31]
Devazepide DMD4N2F Investigative Small molecular drug [32]
EPI-3905 DM41N1U Investigative NA [3]
EPI-6 DMSA7LH Investigative NA [3]
ER-21018 DMUNO4R Investigative NA [33]
FE-203799 DMBX81R Investigative NA [34]
HD-0701 DM59L3U Investigative NA [3]
MDY-1001 DMPX60I Investigative NA [3]
Non GC-C DM8GLO2 Investigative NA [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7471).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 965).
5 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4844).
7 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010679.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3535).
9 ClinicalTrials.gov (NCT00206284) A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.. U.S. National Institutes of Health.
10 ClinicalTrials.gov (NCT01098240) A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression. U.S. National Institutes of Health.
11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033904)
12 ClinicalTrials.gov (NCT03827655) A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery. U.S. National Institutes of Health.
13 Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3697).
15 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
16 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
17 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007365)
18 Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence. BMC Neurosci. 2012 Jun 8;13:63.
19 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017412)
20 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021879)
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003433)
22 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021623)
23 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021622)
24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003724)
25 The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608.
26 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016103)
27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011740)
28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008218)
29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 888).
30 Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol. 2007 May;63(5):618-22.
31 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 878).
33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 250).